Biotheranostics, Inc.

Biotheranostics, Inc.

Cancer diagnostics

Biotheranostics commercialized molecular diagnostic tests for the personalized diagnosis and treatment of breast and other cancers. Hologic acquired Biotheranostics in 2021 for $230 million.